

DermACELL AWM[®]

Human Acellular Dermal Matrix (hADM)

Clinical Overview

Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matrancell[®], a proprietary, patented, and validated processing technology. Matrancell removes a minimum of 97% of donor DNA, allowing for rapid cellular infiltration and re-vascularization. Dermacell AWM is terminally sterilized, ready to use without refrigeration or re-hydration.

Applications


*Chronic Wounds** – Diabetic foot ulcers (DFUs), venous stasis ulcers (VSUs), arterial ulcers, pressure ulcers, dehisced surgical wounds, traumatic burns

** Dermacell AWM can be used over exposed tendon, bone, joint capsule, and muscle*

Features & Benefits

- **Biohospitable:** All cells and \geq 97% donor DNA removed to potentially minimize any adverse patient response.¹
- **Intact Acellular Framework:** Retains native growth factors, collagen and elastin.²
- **Room Temperature Storage:** Ready to use out of the package (15°C- 30°C).
- **Strength:** Pull-out strength and load to failure are comparable to native dermis.^{3,4}
- **Sterile:** Sterilized to a Sterility Assurance Level (SAL) of 10^{-6} , medical device grade sterility.⁵
- **Structural Support:** Facilitates use with sutures, staples.
- **Proven:** Conducted the largest randomized controlled trial (RCT) to date using hADM in chronic wounds.⁵





Dermacell AWM® Advanced Wound Management

Room Temperature (15°C- 30°C)

Size	Thickness	Order Code	Shelf Life
2 x 2 unmeshed	0.2 - 1.0	DCELL100	1.5 years
4 x 4 unmeshed	0.2 - 1.0	DCELL101	3 years
5 x 7 unmeshed	0.2 - 1.0	DCELL102	3 years
6 x 7 unmeshed	0.2 - 1.0	DCELL103	3 years
4 x 8 unmeshed	0.2 - 1.0	DCELL104	3 years
2 x 2 meshed*	0.2 - 1.0	DCELL110	1.5 years
3 x 3 meshed*	0.2 - 1.0	DCELL111	3 years
4 x 4 meshed*	0.2 - 1.0	DCELL112	3 years
5 x 7 meshed*	0.2 - 1.0	DCELL152	3 years
6 x 7 meshed*	0.2 - 1.0	DCELL153	3 years
4 x 8 meshed*	0.2 - 1.0	DCELL154	3 years
5 x 9 meshed*	0.2 - 1.0	DCELL155	3 years
4 x 10 meshed*	0.2 - 1.0	DCELL156	3 years
6 x 10 meshed*	0.2 - 1.0	DCELL157	4 years
8 x 10 meshed*	0.2 - 1.0	DCELL158	4 years
8 x 12 meshed*	0.2 - 1.0	DCELL159	4 years

*Meshed at 1.5:1 ratio

Instructions for use available at LifeNetHealth.org/IFU

References

1. LifeNet Health 10-006, Process PQ, Devitalization of Dermal Allografts.
2. LifeNet Health, TR 0292, LifeNet Health's Decellularized Dermis, DermACELL, Comparison to the USP Monograph, Scaffold Human Dermis.
3. LifeNet Health TR-0119, Assessment of the Impact of Glycerol Treatment and Gamma Irradiation on the Uniaxial Tensile Strength of Acellular Dermis.
4. LifeNet HealthTR-0148, A Preliminary Evaluation of the Suture Retention Strength of Acellular Dermis.
5. LifeNet Health 10-008, Process, PQ, Method 2B Terminal Sterilization Validation for the Devitalized Dermis Allografts Family.
6. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.

